Collaboration and Licensing Revenue - Additional Information (Details)	1 Months Ended					12 Months Ended							24 Months Ended
	Jul. 31, 2022 USD ($)	Jul. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Feb. 29, 2020 USD ($)	Oct. 31, 2012 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) product	Dec. 31, 2015 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2016 USD ($)
Collaboration Agreements [Line Items]
Revenues						$ 26,909,000	$ 14,267,000	$ 31,992,000
Deferred revenue						1,843,000	24,513,000
Long-term portion of deferred revenue						1,818,000	23,023,000
Intrexon Energy Partners And Interxon Energy Partners II
Collaboration Agreements [Line Items]
Capital contribution	$ 7,000,000
Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible										20.00%
License agreement, percentage of operating profits to be received										20.00%
License agreement, annual fee										$ 100,000
License agreement, reimbursement of historical costs									$ 1,000,000
Milestone payments required upon successful achievement, aggregated										210,000,000
License agreement, royalty due, aggregated										$ 100,000,000
License agreement, percentage of sublicensing income										20.00%
Transition period during which costs will be reimbursed										1 year
License agreement, termination, period following triggering event										12 years
Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues	$ 14,561,000					14,661,000	506,000	21,208,000
Deferred revenue						1,818,000	23,023,000
Maximum | Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
Milestone payments required upon successful achievement, per product										$ 52,500,000
License agreement, number of exclusively licensed products | product										4
Alaunos Therapeutics, Inc. | Licensing agreement between Alaunos and Precigen 2018
Collaboration Agreements [Line Items]
License agreement, percentage of development costs for which responsible										80.00%
License agreement, percentage of operating profits to be received										80.00%
License agreement, royalty due, aggregated										$ 50,000,000
Alaunos Therapeutics, Inc. | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues						100,000	100,000	200,000
Deferred revenue										$ 1,855,000
Oragenics, Inc. | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues						0	0	3,053,000
Collaborative agreement, consideration received, value of convertible promissory note											$ 5,000,000
Revenue recognized from previously deferred balances		$ 2,823,000
Castle Creek Biosciences, Inc. | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Revenues						0	388,000	17,810,000
Revenue recognized from previously deferred balances				$ 10,000,000
Collaborative agreement, consideration received, value					$ 7,576,000							$ 7,612,000
Collaborative agreement, consideration received, cash									$ 3,750,000
Royalty rate as a percentage of net sales, tier 1			7.00%
Level of net sales at which royalty rate changes to tier 2			$ 25,000,000
Royalty rate as a percentage of net sales, tier 2			14.00%
Intrexon Energy Partners L.L. and Intrexon Energy Partners II, L.L.C
Collaboration Agreements [Line Items]
Long-term portion of deferred revenue						$ 0	$ 21,205,000
Exotech, Inc.; AD Skincare, Inc.; and Thrive Agrobiotics, Inc. | Collaboration and licensing agreements
Collaboration Agreements [Line Items]
Deferred revenue								$ 6,993,000
Collaborative agreement, consideration received, value													$ 11,000,000